Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion

被引:6
作者
Scott, Ingrid U. [1 ]
Oden, Neal L. [2 ]
Vanveldhuisen, Paul C. [2 ]
Michael, S. [3 ]
Blodi, B. A. [4 ]
机构
[1] Penn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Hershey, PA USA
[2] Emmes, Rockville, MD USA
[3] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA
[4] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
Anti-VEGF treatment; Central retinal vein occlusion; Central subfield thickness visual acuity; Hemiretinal vein occlusion; MACULAR EDEMA SECONDARY; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL TRIAMCINOLONE; LASER TREATMENT; STANDARD-CARE; TRAP-EYE; SHEATHOTOMY; VITRECTOMY; EFFICACY; SAFETY;
D O I
10.1016/j.ophtha.2023.05.023
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with afli-bercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2). Design: Long-term follow-up after a randomized clinical trial from 64 centers in the United States.Participants: Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol.Methods: Two-segment linear regression models were compared with simple linear regression models of VALS on CST. Pearson correlation coefficients were calculated to assess strength of CST and VALS associations.Main Outcome Measures: Central subfield thickness was measured by OCT and VALS by the electronic Early Treatment Diabetic Retinopathy Study methodology. Results: Estimated inflection points, reflecting turning points at which the CST and VALS association changes from positive to negative, calculated at 7 postbaseline visits, range from 217 to 256 mm. A strongly positive cor-relation exists to the left of each estimated inflection point, ranging from 0.29 (P < 0.01 at month 60) to 0.50 (P < 0.01 at month 12), and a strongly negative correlation exists to the right of each estimated inflection point, ranging from-0.43 (P < 0.01 at month 1) to-0.74 (P < 0.01 at month 24). Randomization statistical tests showed that 2-segment models are favored over 1-segment models for all postbaseline months (P < 0.001 for all tests performed).Conclusions: The relationship between CST and VALS in eyes with CRVO or HRVO after treatment with anti-vascular endothelial growth factor (VEGF) therapy is not simply linear. The usually modest correlations between OCT-measured CST and visual acuity belie strong left and right correlations present in 2-segment models. Post-treatment CST close to the estimated inflection points showed the best expected VALS. The SCORE2 participants with a post-treatment CST after treatment close to the estimated inflection points of 217 to 256 mm showed the best VALS. In patients treated with anti-VEGF for macular edema associated with CRVO or HRVO, a thinner retina is not always associated with better VALS. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclo-sures at the end of this article. Ophthalmology 2023;130:1066-1072 (c) 2023 by the American Academy of Ophthalmology
引用
收藏
页码:1066 / 1072
页数:7
相关论文
共 37 条
  • [1] Light "versus "classic'' laser treatment for clinically significant diabetic macular oedema
    Bandello, F
    Polito, A
    Del Borrello, M
    Zemella, N
    Isola, M
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (07) : 864 - 870
  • [2] Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Six-Month Results of the Phase 3 COPERNICUS Study
    Boyer, David
    Heier, Jeffrey
    Brown, David M.
    Clark, W. Lloyd
    Vitti, Robert
    Berliner, Alyson J.
    Groetzbach, Georg
    Zeitz, Oliver
    Sandbrink, Rupert
    Zhu, Xiaoping
    Beckmann, Karola
    Haller, Julia A.
    [J]. OPHTHALMOLOGY, 2012, 119 (05) : 1024 - 1032
  • [3] Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
  • [4] Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema
    Bressler, Susan B.
    Edwards, Allison R.
    Chalam, Kakarla V.
    Bressler, Neil M.
    Glassman, Adam R.
    Jaffe, Glenn J.
    Melia, Michele
    Saggau, David D.
    Plous, Oren Z.
    [J]. JAMA OPHTHALMOLOGY, 2014, 132 (09) : 1113 - 1122
  • [5] Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
    Browning, David J.
    Glassman, Adam R.
    Aiello, Lloyd Paul
    Beck, Roy W.
    Brown, David M.
    Fong, Donald S.
    Bressler, Neil M.
    Danis, Ronald P.
    Kinyoun, James L.
    Nguyen, Quan Dong
    Bhavsar, Abdhish R.
    Gottlieb, Justin
    Pieramici, Dante J.
    Rauser, Michael E.
    Apte, Rajendra S.
    Lim, Jennifer I.
    Miskala, Pdivi H.
    Solomon, Sharon D.
    Bressler, Susan
    Finkelstein, Daniel
    Gehlbach, Peter L.
    Nguyen, Quan Dong
    Sung, Jennifer U.
    Zimmer-Galler, Ingrid
    Doll, Warren
    Donohue, Deborah
    Jurao, Robert
    Sheehan, Siobhan E.
    Belt, Judith
    Sharuk, George S.
    Arrigg, Paul G.
    Schlossman, Deborah K.
    Shah, Sabera T.
    Kopple, Ann
    Stockman, Margaret E.
    Bestourous, Leila
    Calderon, Richard M.
    Cavallerano, Jerry D.
    Chau, Tak
    Cavicchi, Robert W.
    Strong, James
    Wells, John A.
    Clark, Lloyd
    Bearden, Ruth T.
    Taylor, Mallie M.
    Spivey, Robbin
    Evans, Mark A.
    Stone, Marsha L.
    Gardner, Thomas W.
    Neely, Kimberly A.
    [J]. OPHTHALMOLOGY, 2007, 114 (03) : 525 - 536
  • [6] Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study
    Campochiaro, Peter A.
    Heier, Jeffrey S.
    Feiner, Leonard
    Gray, Sarah
    Saroj, Namrata
    Rundle, Amy Chen
    Murahashi, Wendy Yee
    Rubio, Roman G.
    [J]. OPHTHALMOLOGY, 2010, 117 (06) : 1102 - U111
  • [7] Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion
    Çekiç, O
    Chang, S
    Tseng, JJ
    Barile, GR
    Weissman, H
    Del Priore, LV
    Schiff, WM
    Weiss, M
    Klancnik, JM
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (07): : 846 - 850
  • [8] Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema Central Subfield Thickness and Ellipsoid Zone Analysis
    Ciulla, Thomas A.
    Kapik, Barry
    Grewal, Dilraj S.
    Ip, Michael S.
    [J]. OPHTHALMOLOGY RETINA, 2021, 5 (07): : 633 - 647
  • [9] REGRESSION BY LOCAL FITTING - METHODS, PROPERTIES, AND COMPUTATIONAL ALGORITHMS
    CLEVELAND, WS
    DEVLIN, SJ
    GROSSE, E
    [J]. JOURNAL OF ECONOMETRICS, 1988, 37 (01) : 87 - 114
  • [10] Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator
    García-Arumí, J
    Martinez-Castillo, V
    Boixadera, A
    Blasco, H
    Corcostegui, B
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2004, 24 (04): : 530 - 540